PROSTATE CANCER

Treatment of prostate cancer patients with life expectancy and social relations, family and economic situation correspond to the current surgery and radiotherapy only hope to cure prostate cancer, but only a small number of patients suitable for both therapy. Many palliative therapy only, can ease symptoms, but the patient will not have an impact on survival. Therefore, treatment should be integrated in all aspects, the development of rational treatment programs. Current clinical treatment methods used as follows:

1. Endocrine therapy of prostate cancer with typical hormone-dependent, in clinical endocrine treatment of prostate lesions and can significantly ease symptoms, but with no obvious impact on survival.

Many patients may be given the long-term local control, or even cured. But the administration can be a lot of factors such as tumor grade, stage and PSA levels before treatment, even for a partial clinical prostate cancer patients. Tumor-level low, confined to the organ survival rate of patients with prostate and substance cancer is the same age group. some localized prostate cancer in elderly patients, especially well-differentiated, may need treatment (for example, be observed), the risk of death due to other causes than of prostate cancer. but most patients choose radical prostatectomy or radiotherapy. For more age Light patients, radical prostatectomy may be the best, be a long life expectancy, the risk of urinary incontinence in the smallest (about 2%). about 50% of patients can maintain erectile function (eg, at least you can retain a nerve plexus). radiotherapy can have similar results, and special other treatment in patients with low levels of PSA. the standard radiation therapy in general to seven weeks with 70Gy (7000rad) exposure. 3D technology to safely increase the exposure amounted to CAT (8000rad), preliminary data show that higher local control rate. interstitial radiation (radioactive seed implantation) it had the same effect yet to be assessed.